经皮介入微波热凝治疗实验性VX2肺癌的有效性与安全性

Efficacy and Safety of Percutaneous Microwave Coagulation Therapy for Experimental VX2 Lung Cancer in Rabbits

背景与目的:经皮微波热凝治疗(percutaneous microwave coagulation therapy,PMCT)是一种重要的实体肿瘤微创介入治疗方法。本研究评价新型国产微波肿瘤治疗仪及气冷循环微波刀经皮穿刺介入治疗肺VX2移植肿瘤的安全性及有效性。方法:用组织块悬液注射法在30只新西兰大白兔中建立实验性VX2肺癌模型,随机分为对照组、治疗A组(40W×120s)、B组(80W×60s)。在CT引导下经皮穿刺,并按预设参数进行微波热凝治疗;对照组予以假性治疗。观察实验兔术后一般状况,定期CT检查观察肿瘤进展情况,在治疗后第0、1、7天每组随机解剖1只实验兔观察局部组织学改变。结果:肿瘤细胞种植成功率100%。肺癌模型制作成功率为86.7%(26/30)。对照组、治疗A组和B组的生存期分别为(39.7±5.3)天、(62.2±4.4)天和(61.7±4.5)天(P<0.01)。气胸的发生情况分别为33.3%(2/6)、55.6%(5/9)和33.3%(3/9)(P>0.10)。结论:PMCT是一种安全、有效、微创的治疗方法,可为肺癌的介入治疗提供一种新的选择。

BACKGROUND ＆ OBJECTIVE： Percutaneous microwave coagulation therapy （PMCT） is an important mini-invasive technique used to treat solid tumors. This study was to evaluate the efficacy and safety of PMCT with a new homemade equipment for experimental VX2 lung carcinoma in rabbits, and optimize technical parameters. METHODS： VX2 lung cancer model was established in 30 New Zealand rabbits by tissue clot suspension injection. The rabbits were divided into 3 groups： the rabbits in control group received sham operation; those in surgical A group and surgical B group were treated with computed tomography （CT）-guided PMCT at 40 W for 120 s or at 80 W for 60 s. General status of the rabbits after operation were observed. The rabbits were scanned with CT weekly to monitor tumor growth. Right after or 1 or 7 days after operation, 1 rabbit in each group was killed randomly for histologic examination. RESULTS： The success rate of tumor cell transplatation was 100%. The tumor formation rate was 86.7%. The mean survival time was significantly longer in surgical A group and surgical B group than in control group [（62.2±4.4） days and （61.7±4.5） days vs. （39.7±5.3） days, P〈0.01]. The occurrence rates of pneumothorax after PMCT were 33.3% （2/6） in control group, 55.6% （5/9） in surgical A group, and 33.3% （3/9） in surgical B group （P〉0.10）. CONCLUSION： PMCT is a safe, effective and mini-invasive therapeutic option for lung cancer.